LIFETIME OMICS, INC.

Medtech · Private

CLAIRE, an AI platform for analyzing saliva metagenome sequencing data to predict disease progression in viral respiratory infections like COVID-19

Grants
$279K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
$300K
1 award · Health and Human S
#420 of 4531 in medtech
Patents
1
1 granted · 0 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · In Vivo Cluster AI Prediction (CLAIRE) of COVID-19 Disease Progression$248,723
Federal grantDepartment of Health and Human Services · Phase I · In Vivo Cluster AI Prediction (CLAIRE) of COVID-19 Disease Progression$30,166
Federal contractDepartment of Health and Human Services · SBIR Phase I - Topic 123$299,943
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
417AEROPHASE, INC.$304K—
418CORGENIX MEDICAL CORPORATION$301K—
419TheraNano LLC$300K—
420LIFETIME OMICS, INC.$300K—
421ESPER BIOSCIENCES INC$300K—
422DARWIN BIOSCIENCES, INC.$299K—
423SEVIDENT, INC.$299K—

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 1

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.